Member Info for Geovanni

It is old news but not everyone here has been around even 3 months. It is relevant because when France approves Extavia it will have a positive impact on the Synairgen product, in my opinion.

https://www.reuters.com/article/health-coronavirus-france-therapies/france-hopeful-about-use-of-interferon-as-covid-19-therapy-health-minister-idUSP6N2JG02N

This is why it is interesting. Our pal Olivier Veran said nice things about something quite similar back in February

Matterhorn
Thanks for the info.
So is this a new development or has it been this way for a good while - i.e. Physician driven?

Thank you tomphys.

Could someone post the link to the ADVFN board. I lost it when my computer packed up.
Thanks

Line 256 refers to research by Jagannathan. Here it is below - using peginterferon subcutaneous. We already know this isn't much good.

https://www.nature.com/articles/s41467-021-22177-1

My last sentence on the previous message was an attempt at humour.

Prion25
The lines 257-260 are not specific to the interferon treatment they refer to as being of the inhaled type. I suspect they are referring to treatment of the injected type. We know inhaled is far more targeted and therefore more efficacious. How do you control dosage of inhaled when administered to these type of animals. It would require a particularly impressive respiratory mask arrangement.

The article reads like an advert for a quack product. And it can be bought for $49 including shipping! The last sentence as good as admits it's a sales pitch, by mockingly comparing it to bleach.

Taverham

I'm sorry to advise that your email to RM might be of the type he isn't going to answer. I do not think inhaled saline as a treatment will threaten the SNG001 business case,. I am confident it doesn't work.

I mean next news could be progression to ACTIV3. If we follow the BRI 196&198 timetable this could occur quite soon. I was a bit surprised RM didn't mention the USA support.

We could be waiting months for Phase 3 international trial results. The most hopeful news short term is likely to be ACTIV 2 to ACTIV 3 followed by close monitoring of ACTIV 3 efficacy. I don't see USA death rates ever falling to less than 400 per day, so they should be keen to have a treatment that reduces this number of fatalities. Whereas in the UK there isn't the same urgency. Another piece of news will should be the French approval of Extavia which could lead to an EUA for Synairgen.

No. Nothing to do with patent waivers. If another company wants to copy the vaccines they'll come unstuck as they don't know how to make it. Also for the SNG001 treatment, Synairgen isnt going to give any knowledge away, except under licence. I think it is the lack of news that is causing the share price to fall.

I think HMRC has better things to do than collect millions of PI trade data every day. That is why brokers supply HMRC with no data whatsoever. if you accountant tells you otherwise it because he/she wants you to tell the truth.

https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021

One has to look at the left column (2020) to find the single approval - Remdesivir

Good find Owl11.

The best news of the day

I agree. I've just bought another 5000. W

With India issuing EUA for Regeneron in the last 24hrs, it can't be long before they do the same with SNG001. Any day now we can expect USA to progress SNG001 to ACTIV 3. Next month we can expect France to approve their inhaled interferon product - Extavia. That can be seen as an endorsement for Synairgen.

That is interesting . Well found Titiana. So who will be providing the product for these inhalation devices/ Sounds like an RNS might be due soon.

Tornadotony

Could you advise us all what questions who have asked Synairgen and Paraxel. Was getting more P3 trialists in India one of them?
Thank you.

RM's comment on Friday regarding India was that he is willing to have a conversation if India bothered to call him. India is now recruiting in the Phase 3 trial. I suspect that is all it amounts to. A licencing agreement with an Indian Pharma company would make a lot of sense.

However it has nothing to do with Synairgen